Panacea Biotec Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
1,302
- Stock Symbol
-
531349
- Investments
-
1
- Share Price
-
$5.11
- (As of Monday Closing)
Panacea Biotec General Information
Description
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
Contact Information
Website
www.panaceabiotec.comCorporate Office
- B-1 Extention A-27
- Mohan Co-op. Industrial Estate, Mathura Road
- New Delhi, Delhi 110044
- India
Corporate Office
- B-1 Extention A-27
- Mohan Co-op. Industrial Estate, Mathura Road
- New Delhi, Delhi 110044
- India
Panacea Biotec Stock Performance
As of 24-Mar-2025, Panacea Biotec’s stock price is $5.11. Its current market cap is $313M with 61.3M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.11 | $5.18 | $1.36 - $5.76 | $313M | 61.3M | 23.2K | -$0.02 |
Panacea Biotec Financials Summary
As of 31-Dec-2024, Panacea Biotec has a trailing 12-month revenue of $66.4M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 276,114 | 69,036 | 47,106 | 210,263 |
| Revenue | 66,420 | 66,669 | 56,903 | 88,477 |
| EBITDA | 2,336 | 3,924 | 5,501 | 224,081 |
| Net Income | (946) | (142) | (4,139) | 144,726 |
| Total Assets | 148,773 | 154,830 | 231,954 | |
| Total Debt | 0 | 1,799 | 2,463 | 4,504 |
Panacea Biotec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Panacea Biotec Comparisons
Industry
Financing
Details
Panacea Biotec Competitors (40)
One of Panacea Biotec’s 40 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Alkem Laboratories | Formerly PE-Backed | Mumbai, India | ||||
| Abbott India | Corporation | Mumbai, India |
Panacea Biotec Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Panacea Biotec Patents
Panacea Biotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11123420-B2 | Stable live attenuated recombinant dengue vaccine | Active | 30-Sep-2015 | ||
| EP-3355916-A1 | Stable live attenuated recombinant dengue vaccine | Pending | 30-Sep-2015 | ||
| US-20180289793-A1 | Stable live attenuated recombinant dengue vaccine | Active | 30-Sep-2015 | ||
| EP-3355916-A4 | Stable live attenuated recombinant dengue vaccine | Pending | 30-Sep-2015 | ||
| EP-2755722-B1 | Novel sglt inhibitors | Inactive | 13-Sep-2011 | C07D309/10 |
Panacea Biotec Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Panacea Biotec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Panacea Biotec Investments (1)
Panacea Biotec’s most recent deal was a Later Stage VC with Cambridge Biostability for . The deal was made on 06-Dec-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cambridge Biostability | 06-Dec-2006 | Later Stage VC | Biotechnology |
Panacea Biotec Exits (1)
Panacea Biotec’s most recent exit was on 06-Dec-2006 from Cambridge Biostability. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cambridge Biostability | 06-Dec-2006 | Completed |
|
Panacea Biotec FAQs
-
When was Panacea Biotec founded?
Panacea Biotec was founded in 1984.
-
Where is Panacea Biotec headquartered?
Panacea Biotec is headquartered in New Delhi, India.
-
What is the size of Panacea Biotec?
Panacea Biotec has 1,302 total employees.
-
What industry is Panacea Biotec in?
Panacea Biotec’s primary industry is Pharmaceuticals.
-
Is Panacea Biotec a private or public company?
Panacea Biotec is a Public company.
-
What is Panacea Biotec’s stock symbol?
The ticker symbol for Panacea Biotec is 531349.
-
What is the current stock price of Panacea Biotec?
As of 24-Mar-2025 the stock price of Panacea Biotec is $5.11.
-
What is the current market cap of Panacea Biotec?
The current market capitalization of Panacea Biotec is $313M.
-
What is Panacea Biotec’s current revenue?
The trailing twelve month revenue for Panacea Biotec is $66.4M.
-
Who are Panacea Biotec’s competitors?
Biocon, Glenmark Pharmaceuticals, Zydus Lifesciences, Alkem Laboratories, and Abbott India are some of the 40 competitors of Panacea Biotec.
-
What is Panacea Biotec’s annual earnings per share (EPS)?
Panacea Biotec’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
